REIMBURSED PHARMACOTHERAPY OF METASTATIC CLEAR CELL KIDNEY CANCER (MCCKC) IN THE CZECH REPUBLIC
Author(s)
Mazelova J, Slaby J
State Institute for Drug Control, Prague, Czech Republic
Presentation Documents
OBJECTIVES: Concise analysis of reimbursement of drugs for mCCKC. Evaluation was performed from the aspect of the regulator; it regards drugs approved for use in outpatient care. The aim was to identify the development of criteria that must be met by reimbursed drugs, with regard to pharmacoeconomics and evidence-based medicine data. METHODS: We performed a search of the database of administrative proceedings (including proceedings on reimbursement determination as well as on reimbursement revisions) and detected those in which the Decision has already been made. Subsequently, an analysis of submitted evidence was carried out in cases where the reimbursement conditions were first set or amended. RESULTS: Between Jan/2008 and Jun/2014, decisions were issued in 25 relevant proceedings regarding 9 drugs. Before 2008 (when the pricing and reimbursement decision competence was transferred to the Institute) only interpheron-alpha (IFN) and interleukin-2 (IL2) were reimbursed in this indication. The proceedings carried out by the Institute led in IFN and IL2 only to precision of the conditions to better reflect real clinical practice (obsolete regimens were left out). In IL2 the reimbursement conditions for the 1st line of treatment were extended to include the combination with bevacizumab (no pharmacoeconomics required as the evidence had already been assessed and relevant conditions approved for bevacizumab). For the other medicines, the reimbursement conditions were set or amended based on scientific evidence and pharmacoeconomics (1st line: sunitinib ICER/LYG: 25,9 t€, sorafenib ICER/PFLY: 42,8 t€, bevacizumab: 96,3 t€; 1st and 2nd line: pazopanib - CMA analysis vs. sunitinib; 2nd line: axitinib ICER/QALY 57,0 t€, 2nd or 3rd line: everolimus: ICER per LYG: 6,9 t€, ICER; temsirolimus: only costs per LYG: 13,7 t€). CONCLUSIONS: Setting the reimbursement conditions depended not only on the submitted evidence and pharmacoeconomic data but also on other elements (public interest, burden of the disease).
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCN249
Topic
Health Policy & Regulatory
Topic Subcategory
Reimbursement & Access Policy
Disease
Oncology